Close Menu
    What's Hot

    Trump’s American Bitcoin Mining Company to Officially Go Public

    Will Bitcoin hodlers be the reason more countries adopt wealth taxes?

    Michael Saylor’s ‘Strategy’ Buys 13,390 Bitcoin Worth $1.34 Billion

    Facebook X (Twitter) Instagram
    MarketsNews.co.uk
    • Live Chart
    • Brokers
    • Scam Broker
    • Reviews
    • Tools
      • Lot Size Calculator
      • Margin Calculator
      • PIPS Calculator
      • Profit & loss calculator
    Facebook X (Twitter) Instagram
    Start Trading
    Trending Topics:
    • Markets
    • Stocks
    • Cryptocurrency
    • Forex
    • Scam Broker
    MarketsNews.co.uk
    • Markets
    • Stocks
    • Cryptocurrency
    • Forex
    • Scam Broker
    Markets

    Want an Extra $1,000 of Dividend Income in 2025? Invest $11,400 in These 3 High-Yield Stocks.

    Anthony M. OrbisonBy Anthony M. OrbisonDecember 7, 2024No Comments4 Mins Read
    Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    If you’re trying to secure a stream of passive income to support your retirement dreams, there’s more than one way to make it happen. Buying rental properties is an easy-to-understand option you’re probably already familiar with. Unfortunately, owning rental properties comes with day-to-day responsibilities that most retirees would rather avoid.

    If you want to build a truly passive income stream, you’re probably much better off buying dividend-paying stocks and holding them over the long term. Pfizer (NYSE: PFE), PennantPark Floating Rate Capital (NYSE: PFLT), and Ares Capital (NASDAQ: ARCC) offer ultra-high yields that average 8.8% at recent prices. With an average yield this high, an investment of $11,400 spread evenly among them is enough to set you up with $1,000 in annualized dividend income.

    Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

    If there’s one thing income-seeking investors can count on, it’s steadily rising demand for prescription drugs. As one of the world’s largest drugmakers, Pfizer has already raised its dividend payout for 15 consecutive years. At recent prices, it offers a 6.7% yield.

    Pfizer’s share price tanked in 2023 in response to rapidly falling COVID-19 product sales. It’s remained depressed because some of its largest revenue streams, such as the oral blood thinner Eliquis, could lose patent-protected exclusivity over the next few years.

    Upcoming patent cliffs will pressure the growth rate of Pfizer’s dividend payout in the coming decade. With plenty of new revenue streams coming online, though, they probably won’t stop the company from raising its payout for another 15 years.

    Pfizer made a lot of investments with its COVID-19 vaccine windfall, and many are succeeding. In the first nine months of 2024, sales of its COVID-19 vaccine plummeted by 66% to $2.0 billion. Despite the loss, total revenue climbed by 3% year over year.

    The FDA approved nine new drugs from Pfizer’s productive development pipeline in 2023. In the U.S., where those new drugs are already driving growth, product sales soared 27% year over year during the first nine months of 2024.

    PennantPark Floating Rate Capital is a business development company (BDC), which means it lends to mid-sized businesses. American banks have been less inclined to lend directly to businesses for decades.

    Mid-sized businesses starved for capital borrow at rates you might find surprising. The average yield on debt investments in this BDC’s portfolio was 11.5% at the end of September.

    At recent prices, PennantPark Floating Rate Capital offers an 11.1% yield and convenient monthly payments. The BDC has raised or maintained its payout since it started paying dividends in 2011.

    This BDC’s underwriting team has a terrific track record. At the end of September, just two borrowers representing 0.4% of its portfolio were on non-accrual status.

    Ares Capital is the largest publicly traded BDC with a portfolio more than 13 times larger than PennantPark’s. At recent prices, it offers an 8.7% yield and the confidence that comes with a highly experienced underwriting team.

    The average member of Ares Capital’s investment committee has been at it for 30 years, and the experience shows. At the end of September, just 1.3% of this BDC’s portfolio was on non-accrual status.

    If you’re at all nervous about what’s in store for the U.S. economy, it’s hard to find a safer stock. Despite some serious economic downturns, Ares Capital boasts a cumulative net realized loss rate of 0% on investments over the past two decades.

    If you include dividends, this stock delivered a 13% average annual return from 2004 through the present. Adding some shares to a diversified portfolio now to hold for the next 20 years looks like a smart move for just about any investor.

    Before you buy stock in Pfizer, consider this:

    The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

    Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $872,947!*

    Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

    See the 10 stocks »

    *Stock Advisor returns as of December 2, 2024

    Cory Renauer has positions in Ares Capital. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

    Want an Extra $1,000 of Dividend Income in 2025? Invest $11,400 in These 3 High-Yield Stocks. was originally published by The Motley Fool

    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
    Previous ArticleUniCredit says ready to sit down with Credit Agricole over Banco BPM By Reuters
    Next Article Why Trump Must End Capital Gains Tax On Bitcoin
    Anthony M. Orbison
    • Website

    Related Posts

    Where Analysts Think Bitcoin is Headed in 2025

    December 23, 2024

    Fed says it is weighing changes to bank tests for systemic risk

    December 23, 2024

    Housing crisis: Mobile home prices soar faster than single-family homes

    December 23, 2024
    Leave A Reply Cancel Reply

    Amazon.com, Inc.
    $207.43
    $14.37
    7.44%
    Meta Platforms, Inc.
    $634.03
    $41.54
    7.01%
    S&P 500
    $5,813.95
    $154.04
    2.72%
    Alphabet Inc.
    $159.65
    $5.27
    3.41%
    EUR/USD
    $1.11
    $0.0151
    1.34%
    EUR/JPY
    $164.61
    $1.08
    0.66%
    USD/CAD
    $1.40
    $0.0068
    0.49%

    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    We're social. Connect with us:

    Facebook X (Twitter)
    • Home
    • About us
    • Contact
    • Disclaimer
    • Privacy Policy
    © 2025 Marketsnews.co.uk

    Type above and press Enter to search. Press Esc to cancel.